$CNSP
CNS Pharmaceuticals, Inc.

2022 Q4 Form 10-Q Financial Statement

#000168316822007532 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.153M $1.211M $1.235M
YoY Change 140.15% -1.97% 27.36%
% of Gross Profit
Research & Development $3.349M $2.208M $2.578M
YoY Change 76.6% -14.36% 147.89%
% of Gross Profit
Depreciation & Amortization $2.380K $2.800K $3.370K
YoY Change -31.81% -16.91% -66.3%
% of Gross Profit
Operating Expenses $5.502M $3.419M $3.813M
YoY Change 97.0% -10.34% 89.72%
Operating Profit -$3.419M -$3.813M
YoY Change -10.34%
Interest Expense -$2.310K $538.00 -$950.00
YoY Change 3.13% -156.63%
% of Operating Profit
Other Income/Expense, Net -$538.00 -$947.00
YoY Change -43.19%
Pretax Income -$5.504M -$3.420M -$3.814M
YoY Change 96.92% -10.35% 89.77%
Income Tax
% Of Pretax Income
Net Earnings -$5.504M -$3.420M -$3.814M
YoY Change 96.92% -10.35% 89.77%
Net Earnings / Revenue
Basic Earnings Per Share -$0.09 -$0.14
Diluted Earnings Per Share -$3.71 -$0.09 -$139.0K
COMMON SHARES
Basic Shares Outstanding 40.03M shares 40.03M shares 27.44M shares
Diluted Shares Outstanding 40.03M shares 27.44M shares

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.06M $7.027M $8.326M
YoY Change 100.93% -15.6% 535.59%
Cash & Equivalents $10.06M $7.027M $8.326M
Short-Term Investments
Other Short-Term Assets $2.509M $1.673M $2.830M
YoY Change 1.47% -40.88% 133.85%
Inventory
Prepaid Expenses $1.673M
Receivables
Other Receivables
Total Short-Term Assets $12.56M $8.700M $11.16M
YoY Change 68.03% -22.01% 342.69%
LONG-TERM ASSETS
Property, Plant & Equipment $5.664K $8.522K $17.53K
YoY Change -64.84% -51.39% -41.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $482.8K $929.0K $334.1K
YoY Change -61.8% 178.04% -24.06%
Total Long-Term Assets $488.5K $937.6K $351.7K
YoY Change -61.84% 166.61% -25.18%
TOTAL ASSETS
Total Short-Term Assets $12.56M $8.700M $11.16M
Total Long-Term Assets $488.5K $937.6K $351.7K
Total Assets $13.05M $9.638M $11.51M
YoY Change 49.05% -16.25% 284.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.682M $1.005M $1.462M
YoY Change 141.78% -31.24% 484.63%
Accrued Expenses $828.4K $200.0K $901.2K
YoY Change 268.26% -77.81% 246.62%
Deferred Revenue
YoY Change
Short-Term Debt $449.9K $39.26K $44.63K
YoY Change 5.61% -12.03%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.920M $1.244M $2.407M
YoY Change 130.4% -48.31% 372.05%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.920M $1.244M $2.407M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $4.920M $1.244M $2.407M
YoY Change 130.4% -48.31% 372.05%
SHAREHOLDERS EQUITY
Retained Earnings -$50.72M -$44.75M
YoY Change 44.97%
Common Stock $1.617K $40.03K
YoY Change -94.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.133M $8.394M $9.100M
YoY Change
Total Liabilities & Shareholders Equity $13.05M $9.638M $11.51M
YoY Change 49.05% -16.25% 284.87%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$5.504M -$3.420M -$3.814M
YoY Change 96.92% -10.35% 89.77%
Depreciation, Depletion And Amortization $2.380K $2.800K $3.370K
YoY Change -31.81% -16.91% -66.3%
Cash From Operating Activities -$2.305M -$1.813M -$1.996M
YoY Change -28.78% -9.16% 57.13%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$1.510K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$1.510K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $3.569M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.333M -117.1K 3.436M
YoY Change -6538.8% -103.41% -6972.34%
NET CHANGE
Cash From Operating Activities -2.305M -1.813M -1.996M
Cash From Investing Activities 0.000 -1.510K 0.000
Cash From Financing Activities 5.333M -117.1K 3.436M
Net Change In Cash 3.028M -1.931M 1.441M
YoY Change -191.16% -234.07% -209.14%
FREE CASH FLOW
Cash From Operating Activities -$2.305M -$1.813M -$1.996M
Capital Expenditures $0.00 -$1.510K $0.00
Free Cash Flow -$2.305M -$1.811M -$1.996M
YoY Change -28.73% -9.23% 57.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001729427
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39126
dei Entity Registrant Name
EntityRegistrantName
CNS Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2318545
dei Entity Address Address Line1
EntityAddressAddressLine1
2100 West Loop South
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 900
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77027
dei City Area Code
CityAreaCode
800
dei Local Phone Number
LocalPhoneNumber
946-9185
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
CNSP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
40032481 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7027470 usd
CY2022Q3 us-gaap Assets
Assets
9637927 usd
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
1279935 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5004517 usd
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1672899 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2472933 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
8700369 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
7477450 usd
CY2022Q3 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
594898 usd
CY2021Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
929688 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8522 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16109 usd
CY2022Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
334138 usd
CY2021Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
334138 usd
CY2022Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
937558 usd
CY2021Q4 us-gaap Assets
Assets
8757385 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1005043 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1522823 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
200000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
224949 usd
CY2022Q3 us-gaap Notes Payable Current
NotesPayableCurrent
39260 usd
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
387794 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1244303 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2135566 usd
CY2022Q3 us-gaap Liabilities
Liabilities
1244303 usd
CY2021Q4 us-gaap Liabilities
Liabilities
2135566 usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40032481 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40032481 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27927217 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27927217 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
40032 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
27927 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
53106357 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
41576813 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44752765 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-34982921 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
8393624 usd
us-gaap Operating Expenses
OperatingExpenses
9765129 usd
us-gaap Operating Expenses
OperatingExpenses
11234378 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3419015 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
6621819 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9637927 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8757385 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1211102 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1235385 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3814513 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3784509 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2207913 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2578016 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5950616 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7449869 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
3419015 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
3813401 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3813401 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-9765129 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-11234378 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
538 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
947 usd
us-gaap Interest Expense
InterestExpense
4715 usd
us-gaap Interest Expense
InterestExpense
7047 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-538 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-947 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4715 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7047 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3419553 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3814348 usd
us-gaap Net Income Loss
NetIncomeLoss
-9769844 usd
us-gaap Net Income Loss
NetIncomeLoss
-11241425 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40032481 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27443771 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39631939 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25858221 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40032481 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27443771 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39631939 shares
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
336685 usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25858221 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
6621819 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10625786 usd
CY2022Q1 CNSP Stock Issued For Exercise Of Warrants
StockIssuedForExerciseOfWarrants
2616 usd
CY2021Q1 CNSP Stock Issued For Exercise Of Warrants
StockIssuedForExerciseOfWarrants
332750 usd
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
430679 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3613404 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
11242852 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10625786 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4653821 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2784339 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
14802567 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
286841 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3565952 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
11523456 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
289721 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3419553 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
8393624 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
13947984 usd
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
144843 usd
CY2021Q2 CNSP Common Stock Issued For Cash And Subscription Receivable Net
CommonStockIssuedForCashAndSubscriptionReceivableNet
4508978 usd
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
469610 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3813673 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
12407767 usd
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
506647 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3814348 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
9100066 usd
us-gaap Net Income Loss
NetIncomeLoss
-9769844 usd
us-gaap Net Income Loss
NetIncomeLoss
-11241425 usd
us-gaap Share Based Compensation
ShareBasedCompensation
913247 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1406936 usd
us-gaap Depreciation
Depreciation
9375 usd
us-gaap Depreciation
Depreciation
9577 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-2635 usd
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-0 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1134824 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1373257 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-517780 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
515244 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-24949 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
381418 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8252492 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10301507 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4423 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3672 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4423 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3672 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
348534 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
394662 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2616 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
332750 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10279868 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4591909 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2022953 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CNSP Cashless Exercise Of Warrants
CashlessExerciseOfWarrants
0 usd
CNSP Cashless Exercise Of Warrants
CashlessExerciseOfWarrants
1296 usd
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-5713270 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5004517 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14039493 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7027470 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8326223 usd
us-gaap Interest Paid Net
InterestPaidNet
5782 usd
us-gaap Interest Paid Net
InterestPaidNet
7207 usd
us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_80E_eus-gaap--NatureOfOperations_zt9XAAYws3g2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 – <span id="xdx_826_z8UtMNakZHIk">Nature of Business</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CNS Pharmaceuticals, Inc. (“we”, “our”, the “Company”) is a clinical pharmaceutical company organized as a Nevada corporation on July 27, 2017 to focus on the development of anti-cancer drug candidates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
6777470 usd
CY2021Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
425990 usd
CY2021Q4 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.033 pure
CY2021Q4 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2022-09-30
CY2022Q3 us-gaap Notes Payable Current
NotesPayableCurrent
39260 usd
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
387794 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y11M23D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
36850 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2616 usd
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P4Y
us-gaap Labor And Related Expense
LaborAndRelatedExpense
76087 usd
CY2021 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
800000 usd
CY2020Q2 us-gaap Payments For Fees
PaymentsForFees
775000 usd
CY2020Q2 us-gaap Development Costs
DevelopmentCosts
1000000.0 usd

Files In Submission

Name View Source Status
0001683168-22-007532-index-headers.html Edgar Link pending
0001683168-22-007532-index.html Edgar Link pending
0001683168-22-007532.txt Edgar Link pending
0001683168-22-007532-xbrl.zip Edgar Link pending
cnsp-20220930.xsd Edgar Link pending
cns_ex3101.htm Edgar Link pending
cns_ex3102.htm Edgar Link pending
cns_ex3201.htm Edgar Link pending
cns_ex3202.htm Edgar Link pending
cns_i10q-093022.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cnsp-20220930_cal.xml Edgar Link unprocessable
cnsp-20220930_def.xml Edgar Link unprocessable
cnsp-20220930_lab.xml Edgar Link unprocessable
cnsp-20220930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cns_i10q-093022_htm.xml Edgar Link completed